Ajinomoto announces new fermentation initiative to create amino acids Today a fresh initiative to develop propriety fermentation technology for producing cystine and cysteine Ajinomoto announced, amino acids important in several applications, including pharmaceuticals, flavorings, and cosmetics read . Ajinomoto’s expansion in this marketplace will offer additional sourcing choices for manufacturers, since it will make available cysteine and cystine that are made by microbial fermentation of starches and/or sugars. The largest portion of the cystine and cysteine demand presently is met by manufacturers who extract these amino acids from recycleables of pet origin. ‘Our customers around the world are a lot more sensitive to the nature and quality of recycleables used in meals, pharma and cosmetic production,’ said Mike Lish, Director of Sales and Marketing at Ajinomoto.
Akorn launches generic Vancocin for treatment of CDAD Akorn, Inc.S. For the twelve months ended December 31, 2011. Akorn has started shipping its U.S. Food and Drug Administration accepted generic edition in both strengths in a 20 capsule pack size.